Juvena Therapeutics makes history with the FDA approval of a new drug for the treatment of type 1 myotonic muscle disease (DM1)
Juvena Therapeutics, which uses artificial intelligence to discover new drugs,
received historic approval from the FDA for JUV-161, a breakthrough drug for the treatment of DM1 disease.
What is DM1?
DM1, or in its full name dystrophic myotonia type 1, is a genetic disease that causes permanent weakening and contraction of the muscles.
As a result, DM1 patients suffer from a significant decrease in their strength and endurance, as well as difficulties in performing daily activities.
DM1 is a common form of adult-onset muscular dystrophy, and can be inherited from parents to children.
The disease affects people of any age, but it usually appears for the first time in early adulthood.
Signs and symptoms of DM1:
- Progressive muscle weakness
- Difficulties in relaxing muscles after exertion (myotonia)
- fatigue
- Walking difficulties
- breathing difficulties
- Difficulty swallowing
- Eye problems
- Cognitive difficulties
The light at the end of the tunnel: JUV-161, a development of advanced artificial intelligence technology, offers new hope for DM1 patients.
The drug works on several levels:
- Restoration of muscle fibers: JUV-161 restores the formation of muscle fibers, a process essential for their strengthening and proper functioning.
- Combating muscle weakness: The medicine fights the muscle weakness that characterizes DM1, and helps to improve their strength and endurance.
- Improving metabolism: JUV-161 has a positive effect on muscle metabolism, contributing to their normal function and preventing degeneration.
Several clinical studies are expected to begin this year, and will allow testing the effectiveness and safety of JUV-161 for the treatment of DM1 in humans.
DM1 causes early signs of aging, so the FDA classifies it as a progeroid disease.
Dr. Hanadi Yossef of Juvena emphasizes that JUV-161 may be a solution to this problem as well,
because it improves the muscle's restoration capabilities, metabolism and function, thus counteracting the effects of aging.
JUV-161 has also been found to be effective in models of age-related muscle diseases, such as sarcopenia and muscle injuries.
Dr. Yosef explains that the development of the drug is initially focused on DM1, but after proving its safety and effectiveness, it will be possible to easily adapt it to the treatment of other age-related diseases.
